In another study, Shukuya and colleagues demonstrated that the concentration of specific circulating miRNAs and miRNAs packaged in extracellular vehicles was significantly different between responder and nonresponder NSCLC patients treated with anti-PD-1/L1 therapy [122]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.